B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 Clinical Trials

6 recruiting

Frequently Asked Questions

Common questions about B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 3

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
National Cancer Institute (NCI)348 enrolled211 locationsNCT04530565
Recruiting
Phase 3

Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma

Mixed Phenotype Acute LeukemiaLymphoblastic LymphomaB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1+3 more
Children's Oncology Group440 enrolled229 locationsNCT05602194
Recruiting
Phase 2

Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

Lymphoblastic LymphomaB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1
University of Washington33 enrolled1 locationNCT07224100
Recruiting
Phase 1

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

Mixed Phenotype Acute LeukemiaB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1B Acute Lymphoblastic Leukemia+2 more
OHSU Knight Cancer Institute20 enrolled1 locationNCT04872790
Recruiting
Phase 1Phase 2

Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia

Recurrent Burkitt LymphomaRefractory Burkitt LymphomaB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1+6 more
M.D. Anderson Cancer Center276 enrolled1 locationNCT01371630
Recruiting
Phase 2

Personalized NK Cell Therapy in CBT

Acute Lymphoblastic LeukemiaMyelodysplastic SyndromeChronic Myelomonocytic Leukemia+23 more
M.D. Anderson Cancer Center100 enrolled1 locationNCT02727803